• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.635 +0.005 (+0.31%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 622,638
Open 1.650
Bid (Size) 1.600 (200)
Ask (Size) 1.700 (100)
Prev. Close 1.630
Today's Range 1.620 - 1.665
52wk Range 1.330 - 3.100
Shares Outstanding 80,817,079
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease ↗
October 02, 2026
ProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid... 
Via MarketBeat
News headline image
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
September 23, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire

Performance

52-Week Range 47.3% below 52-week high
1.635
1.3352W Low 3.1052W High
1 Week 3.8% below 1-week high
1.551W Low 1.701W High

ProQR Therapeutics N.V. - Ordinary Shares (PRQR) traded between $1.33 and $3.10 over the past 52 weeks and last traded at $1.64, 47.3% below its 52-week high. Over the past week it ranged between $1.55 and $1.70.

Past 12 Months
-0.9%
-24.0%
-4.9%
-9.7%
-17.8%
-27.3%
1W -$0.01
1M -$0.51
3M -$0.08
6M -$0.18
YTD -$0.35
1Y -$0.61

PRQR was -27.3% over the past year, -9.7% over six months, -17.8% year to date, -0.9% in the last week.

12 Months vs Market
PRQR
-27.3%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months PRQR returned -27.3% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.71× 3-mo avg
Today 622,638 3-mo avg 871.7K
1W
824.9K
1M
650.0K
3M
871.7K
6M
894.7K
YTD
736.2K
1Y
688.3K

PRQR most recently traded 622,638 shares against a 3-month average daily volume of 871.7K.

More News

Read More
News headline image
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
September 09, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Participate in Upcoming Investor Conferences in September 2026
September 02, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Second Quarter 2026 Operating and Financial Results
August 13, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
June 25, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
June 25, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Quarter 2026 Operating and Financial Results
May 12, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
May 11, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
May 04, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
April 30, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
Wondering what's happening in today's pre-market session? ↗
March 30, 2026
Via Chartmill
News headline image
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
March 25, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Year End 2025 Operating and Financial Results
March 12, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
March 03, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Planned Changes to Board Composition
February 09, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
January 08, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Participate in 8th Annual Evercore Healthcare Conference
December 01, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Third Quarter 2025 Operating and Financial Results
November 06, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
October 20, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
October 16, 2025
Via Chartmill
News headline image
ProQR to Participate in Upcoming Investor Conferences in October 2025
October 13, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
September 16, 2025
Via Benzinga
News headline image
ProQR Announces Second Quarter 2025 Operating and Financial Results
August 07, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Upcoming Presentation at RNA Editing Summit
July 28, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire

Frequently Asked Questions

Is ProQR Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, ProQR Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does ProQR Therapeutics N.V. - Ordinary Shares trade on?
ProQR Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares?
The ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares is PRQR on the Nasdaq Stock Market
What is the current price of ProQR Therapeutics N.V. - Ordinary Shares?
The current price of ProQR Therapeutics N.V. - Ordinary Shares is 1.635
When was ProQR Therapeutics N.V. - Ordinary Shares last traded?
The last trade of ProQR Therapeutics N.V. - Ordinary Shares was at 10/02/26 04:00 PM ET
What is the market capitalization of ProQR Therapeutics N.V. - Ordinary Shares?
The market capitalization of ProQR Therapeutics N.V. - Ordinary Shares is 132.14M
How many shares of ProQR Therapeutics N.V. - Ordinary Shares are outstanding?
ProQR Therapeutics N.V. - Ordinary Shares has 132M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap